• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year

    10/25/24 7:40:00 AM ET
    $RDY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RDY alert in real time by email

    Dr. Reddy's Laboratories Ltd. ("Dr. Reddy's") has been ranked among the top employers according to the 2024 Top Biotech and Pharma Employers Survey conducted by Science.

    This marks the third consecutive appearance of Dr. Reddy's in the list. In 2022, Dr. Reddy's entered the prestigious list at rank 18. In 2023, the company was placed at number 16. In the latest 2024 rankings, Dr. Reddy's is placed at number 15 with high scores in ‘Employee Respect', ‘Employee Loyalty' and ‘Social Responsibility'. The full list is available here: https://www.science.org/content/article/top-20-2024-who-did-science-readers-select-best-biopharma

    The prestigious Science magazine is a U.S.-based peer-reviewed academic journal of the American Association for the Advancement of Science (AAAS) and one of the world's top academic journals. Since 2002, Science magazine has evaluated top organizations in biotech, pharma, and biopharma through its Top Employers Survey. The Science and Science Careers' 2024 Top Employers Survey polled employees in biotechnology, biopharmaceutical, pharmaceutical, and related industries to determine the 20 best employers as well as their driving characteristics. Respondents to the web-based survey were asked to rate companies based on 24 characteristics, including innovative leadership, respect for employees, and social responsibility. The findings are based on approximately 6,400 completed surveys from readers of Science, and other survey invitees.

    Commenting on the recognition, G.V. Prasad, Co-Chairman and Managing Director of Dr. Reddy's said, "We stand for developing affordable and innovative pharmaceuticals by investing in cutting-edge science and technology, developing great scientists and creating an environment that nurtures innovation in all aspects of product development. Our colleagues have the freedom to pursue multiple career tracks within the organization and we expose them to the best ideas and knowledge in whatever field they choose to work in. Our culture and identity have revolved around being bold, entrepreneurial, responsible, humble, empathetic. Our purpose of ‘Good Health Can't Wait' is a movement and call to action for all of us, and good health encompasses patients, people and planet. The opportunity is available to each colleague to do their life's work at our company and make the world a better place. Our people are our pride, and nothing gives us more joy than to see our people realize their full potential in the company."

    A recent report by the Foundation for Advancing Science and Technology (FAST India) in collaboration with IIFL Securities on ‘State of Industry R&D in India' ranked Dr. Reddy's first among Indian pharma companies in both R&D intensity and the proportion of PhD employees1.

    Note on methodology:

    Science Careers, a part of the American Association for the Advancement of Science (AAAS), commissioned Cell Associates and The Brighton Consulting Group to conduct a web-based survey aimed at determining the companies in the biotechnology and pharmaceutical industries with the best reputations as employers. This web-based study was conducted from March 1 through April 7, 2024.

    For this year's survey, a mixed methodology was used. The first part of this methodology included emailed invitations to Science and Science Careers website visitors registered with AAAS as well as several social media posts. The second part of the methodology included email blasts to Human Resource contacts from the Science Careers database, asking them to promote the survey within their organizations.

    This report is based on a total sample of approximately 6,400 surveys. A vast majority of the survey participants came from North America (65%), Europe (19%), and Asia/Pacific Rim (11%).

    Survey respondents were asked to select the companies they considered best, average, and worst employers. They then rated these companies on 24 different attributes. Attribute categories included Corporate Image, Financial Prowess, Leadership and Direction, Work Culture and Environment, and Academic and Intellectual Challenge.

    A mathematical process was used to determine the attributes with the greatest impact on company/employer reputation. Unique ranking scores were then derived from the ratings given to each company on these attributes. The 20 companies with the best reputations as employers were then determined from the list of companies that were each mentioned at least 35 times. The ranking for each company was independent of company size or number of votes.

    About AAAS: The American Association for the Advancement of Science (AAAS) is the world's largest general scientific society and publisher of the journal Science, as well as Science Translational Medicine; Science Signaling; a digital, open-access journal, Science Advances; Science Immunology; and Science Robotics. AAAS was founded in 1848, and includes more than 250 affiliated societies and academies of science, serving 10 million individuals. The nonprofit AAAS is open to all and fulfills its mission to "advance science and serve society" through initiatives in science policy, international programs, science education, public engagement, and more. For additional information about AAAS, see www.aaas.org.

    About Dr. Reddy's: Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY)) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of ‘Good Health Can't Wait', we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.

    __________________________________

    1 https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/indian-pharma-firms-trail-global-peers-in-rd-innovation-and-talent-metrics-fast-india-iifl-securities/articleshow/114395822.cms?from=mdr

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241025692642/en/

    Get the next $RDY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Q&A

    New
    • What is Dr. Reddy's current ranking in the 2024 Top Employers Survey?

      Dr. Reddy's Laboratories Ltd. has improved its ranking to number 15 in the 2024 Top Biotech and Pharma Employers Survey.

    • In which areas did Dr. Reddy's receive high scores in the survey?

      Dr. Reddy's has been recognized for high scores in the categories of ‘Employee Respect', ‘Employee Loyalty', and ‘Social Responsibility'.

    • What does G.V. Prasad highlight about the company culture at Dr. Reddy's?

      G.V. Prasad stated that Dr. Reddy's fosters a culture of boldness, responsibility, and innovation, allowing employees to pursue various career paths and realize their potential.

    • How many survey responses were collected for the 2024 Top Employers Survey?

      The survey received approximately 6,400 completed responses from employees in the biotech and pharmaceutical sectors.

    • What recent recognition did Dr. Reddy's receive regarding its R&D and employment of PhD professionals?

      Dr. Reddy's was ranked first among Indian pharma companies in both R&D intensity and the proportion of PhD employees according to a report by FAST India.

    Recent Analyst Ratings for
    $RDY

    DatePrice TargetRatingAnalyst
    6/5/2025$16.89Hold → Buy
    HSBC Securities
    12/19/2024Buy → Neutral
    Nomura
    1/11/2024Buy → Underperform
    Jefferies
    8/29/2023Buy → Hold
    HSBC Securities
    5/18/2023Outperform → Mkt Perform
    Bernstein
    3/17/2023Neutral → Buy
    BofA Securities
    1/30/2023Underweight
    JP Morgan
    11/14/2022Neutral → Underperform
    Credit Suisse
    More analyst ratings

    $RDY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Dr. Reddy's Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept

    Following the submission in December 2025, USFDA has accepted Dr. Reddy's 351(k) Biologics License Application (BLA) for Proposed Interchangeable biosimilar Abatacept, DRL_AB (IV for Infusion) BLA is based on a robust data package supporting similarity to Orencia® (abatacept) IV for infusion through totality of evidence including pharmacokinetic (PK) data   Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's"), today announced that the US Food and Drug Administration (USFDA) has accepted for review, its 351 (k) Biologics License Application (BLA) IV for infusion formulation for DRL_AB

    2/20/26 10:57:00 AM ET
    $RDY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dr. Reddy's Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.

    Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of over-the-counter (OTC) Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7%, the generic equivalent of Extra Strength Pataday® Once-Daily Relief, in the U.S. market, as approved by the U.S. Food and Drug Administration (USFDA). Dr. Reddy's Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% is an Antihistamine eye drop, indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander. "This launch adds to our current portfolio in the OTC eye-care space which includes Olopatadine H

    1/14/26 8:49:00 AM ET
    $RDY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immutep and Dr. Reddy's enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa

    Dr. Reddy's receives exclusive rights to develop and commercialise Eftilagimod Alfa in all countries outside North America, Europe, Japan, and Greater China Under the terms, Immutep to receive upfront payment of USD 20 million (~AUD 30.2 million) and is also eligible to receive potential regulatory development and commercial milestone payments of up to USD 349.5 million (~AUD 528.4 million), plus double-digit royalties on commercial sales Sydney, Australia/Hyderabad, India, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases and Dr. Reddy's Laboratories Ltd., (

    12/8/25 8:00:00 AM ET
    $IMMP
    $RDY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RDY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Aghanian Patrick Rudolf

    3 - DR REDDYS LABORATORIES LTD (0001135951) (Issuer)

    4/1/26 1:05:10 PM ET
    $RDY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Kalawadia Milan Kantilal

    3 - DR REDDYS LABORATORIES LTD (0001135951) (Issuer)

    4/1/26 12:42:44 PM ET
    $RDY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Motupalli Venkata Ramana

    3 - DR REDDYS LABORATORIES LTD (0001135951) (Issuer)

    4/1/26 11:53:24 AM ET
    $RDY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RDY
    SEC Filings

    View All

    $RDY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    SEC Form 6-K filed by Dr. Reddy's Laboratories Ltd

    6-K - DR REDDYS LABORATORIES LTD (0001135951) (Filer)

    3/26/26 7:18:41 AM ET
    $RDY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Dr. Reddy's Laboratories Ltd

    6-K - DR REDDYS LABORATORIES LTD (0001135951) (Filer)

    3/24/26 11:16:14 AM ET
    $RDY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Dr. Reddy's Laboratories Ltd

    6-K - DR REDDYS LABORATORIES LTD (0001135951) (Filer)

    3/23/26 10:03:38 AM ET
    $RDY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dr. Reddy's upgraded by HSBC Securities with a new price target

    HSBC Securities upgraded Dr. Reddy's from Hold to Buy and set a new price target of $16.90

    6/5/25 7:30:56 AM ET
    $RDY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dr. Reddy's downgraded by Nomura

    Nomura downgraded Dr. Reddy's from Buy to Neutral

    12/19/24 8:23:54 AM ET
    $RDY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dr. Reddy's downgraded by Jefferies

    Jefferies downgraded Dr. Reddy's from Buy to Underperform

    1/11/24 8:20:29 AM ET
    $RDY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RDY
    Leadership Updates

    Live Leadership Updates

    View All

    Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.

    SHANGHAI, Feb. 6, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd., (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as ", Dr. Reddy', s", ) for the company's independently developed investigational daratumumab biosimilar HLX15, a recombinant anti-CD38 fully human monoclonal antibody injection. Dr. Reddy's will gain exclusive rights to commercialize both subcutaneous and intravenous formulation of HLX15 in a total of 43 countries and regions, comprising 42 European countries and

    2/6/25 6:35:00 AM ET
    $RDY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America

    Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as ", Dr. Reddy', s", )), today announced the appointment of Milan Kalawadia as Chief Executive Officer, North America, and member of the Management Council. As part of the Dr. Reddy's senior leadership team, he will be responsible for the company's North America business and will be based out of the Princeton, New Jersey, U.S. office. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240528120424/en/Milan Kalawadia (Photo: Business Wire) "I am excited to start this next chapter in my journey at Dr

    5/28/24 9:53:00 AM ET
    $RDY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RDY
    Financials

    Live finance-specific insights

    View All

    Dr. Reddy's Q1FY26 Financial Results

    Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter ended June 30, 2025. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Q1 FY26 Revenues   ₹ 85,452 Mn [Up: 11% YoY; Flat QoQ] Gross Margin   56.9% [Q1FY25: 60.4%; Q4FY25: 55.6%] SG&A Expenses   ₹ 25,647 Mn [Up: 13% YoY; 7% QoQ] R&D Expenses   ₹ 6,244 Mn [7.3% of Revenues] EBITDA   ₹ 22,784 Mn [26.7% of Revenues] Profit before

    7/23/25 1:46:00 PM ET
    $RDY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dr. Reddy's Q4 & Full Year FY25 Financial Results

    Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter and year ended March 31, 2025. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Q4FY25 FY25   Revenues ₹ 85,060 Mn ₹ 325,535 Mn [Up: 20% YoY^; 2% QoQ] [Up: 17% YoY^]     Gross Margin 55.6% 58.5% [Q4FY24: 58.6%; Q3FY25: 58.7%] [FY24: 58.6%]     SG&A Expenses ₹ 24,055 Mn ₹ 93,870 Mn [Up: 17% YoY; Flat QoQ] [Up: 22% YoY]     R&D Expens

    5/9/25 2:53:00 PM ET
    $RDY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dr. Reddy's Q3 & 9MFY25 Financial Results

    Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter and nine months ended December 31, 2024. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Q3FY25 9MFY25   Revenues ₹ 83,586 Mn ₹ 240,475 Mn [Up: 16% YoY^; 4% QoQ] [Up: 15% YoY^]   Gross Margin 58.7% 59.5% [Q3FY24: 58.5%; Q2FY25: 59.6%] [9MFY24: 58.6%]   SG&A Expenses ₹ 24,117 Mn ₹ 69,815 Mn [Up: 19% YoY; 5% QoQ] [Up: 23% YoY]   R&D Expenses ₹ 6,658 Mn ₹ 20,122 Mn [8.0% o

    1/23/25 12:35:00 PM ET
    $RDY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RDY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Dr. Reddy's Laboratories Ltd

    SC 13D/A - DR REDDYS LABORATORIES LTD (0001135951) (Subject)

    7/1/24 6:44:13 AM ET
    $RDY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Dr. Reddy's Laboratories Ltd (Amendment)

    SC 13D/A - DR REDDYS LABORATORIES LTD (0001135951) (Subject)

    5/2/22 2:44:27 PM ET
    $RDY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - DR REDDYS LABORATORIES LTD (0001135951) (Subject)

    2/2/21 7:05:59 AM ET
    $RDY
    Biotechnology: Pharmaceutical Preparations
    Health Care